Rheumatoid Arthritis (RA) - Pipeline Insight, 2021
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s, “Rheumatoid Arthritis (RA) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Rheumatoid Arthritis (RA): Overview
Rheumatoid arthritis (RA) is a chronic, progressive, and disabling autoimmune disease. Rheumatoid Arthritis (RA) mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. Signs and symptoms of RA include pain or aching in more than one joint, stiffness in more than one joint, tenderness and swelling in more than one joint, weight loss, weakness, fever, and/or fatigue or tiredness. Rheumatoid Arthritis (RA) is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. Treatment for Rheumatoid Arthritis (RA) usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-line treatment.
'Rheumatoid Arthritis (RA) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Rheumatoid Arthritis (RA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rheumatoid Arthritis (RA) Emerging Drugs
Further product details are provided in the report……..
Rheumatoid Arthritis (RA): Therapeutic Assessment
This segment of the report provides insights about the different Rheumatoid Arthritis (RA) drugs segregated based on following parameters that define the scope of the report, such as:
Rheumatoid Arthritis (RA): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis (RA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis (RA) drugs.
Rheumatoid Arthritis (RA) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Rheumatoid Arthritis (RA) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Rheumatoid Arthritis (RA): Overview
Rheumatoid arthritis (RA) is a chronic, progressive, and disabling autoimmune disease. Rheumatoid Arthritis (RA) mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. Signs and symptoms of RA include pain or aching in more than one joint, stiffness in more than one joint, tenderness and swelling in more than one joint, weight loss, weakness, fever, and/or fatigue or tiredness. Rheumatoid Arthritis (RA) is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. Treatment for Rheumatoid Arthritis (RA) usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-line treatment.
'Rheumatoid Arthritis (RA) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis (RA) R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis (RA).
This segment of the Rheumatoid Arthritis (RA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rheumatoid Arthritis (RA) Emerging Drugs
- Ozoralizumab: Taisho Pharmaceutical
- ABX464: Abivax
Further product details are provided in the report……..
Rheumatoid Arthritis (RA): Therapeutic Assessment
This segment of the report provides insights about the different Rheumatoid Arthritis (RA) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Rheumatoid Arthritis (RA)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Rheumatoid Arthritis (RA): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis (RA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis (RA) drugs.
Rheumatoid Arthritis (RA) Report Insights
- Rheumatoid Arthritis (RA) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rheumatoid Arthritis (RA) drugs?
- How many Rheumatoid Arthritis (RA) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis (RA)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis (RA) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rheumatoid Arthritis (RA) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Abivax
- Kymera Therapeutics
- Akari Therapeutics
- Sierra Oncology
- Neutrolis Therapeutics
- Centivax
- Taisho
- Hope Biosciences
- UCB
- Galmed Pharmaceuticals
- Celon Pharma
- Jiangsu Hengrui Medicine Co.
- Cyxone
- Oryn Therapeutics
- ABX464
- KT 474
- Nomacopan
- Momelotinib
- NTR 441
- Anti-CXCR5 antibody
- Ozoralizumab
- HB adMSCs
- Olokizumab
- Amilo-5MER
- CPL-409116
- SHR 0302
- Rabeximod
- ORTD 1
Introduction
Executive Summary
Rheumatoid Arthritis (RA): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Rheumatoid Arthritis (RA) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
SHR 0302: Jiangsu Hengrui Medicine Co.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABX464: Abivax
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Amilo-5MER: Galmed Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
KT 474: Kymera Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Appendix
Executive Summary
Rheumatoid Arthritis (RA): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Rheumatoid Arthritis (RA) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
SHR 0302: Jiangsu Hengrui Medicine Co.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABX464: Abivax
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Amilo-5MER: Galmed Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
KT 474: Kymera Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Rheumatoid Arthritis (RA)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Rheumatoid Arthritis (RA)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Rheumatoid Arthritis (RA)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Rheumatoid Arthritis (RA)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
